Groupon’s Largest Shareholder Makes Another Exec Change, Appoints New CFO

Groupon Inc (NASDAQ:GRPN) announced the transition of CFO today.  The company announced the appointment of Jiri Ponrt as the new…
  • Groupon Inc (NASDAQ:GRPN) announced the transition of CFO today. 
  • The company announced the appointment of Jiri Ponrt as the new Chief Financial Officer, who will succeed Damien Schmitz.
  • “A key part of his role will be to significantly improve internal processes, controls and financial reporting. Beyond his financial credentials, Jiri has the necessary leadership and communication skills to translate detailed information into clear, concise and accessible messaging, a vital skill as we look to unlock Groupon’s full potential and super-charge our transformation.” stated Dusan Senkypl, Interim CEO. 
  • Ponrt is joining Groupon from Pale Fire Capital, which is Groupon’s largest shareholder and holds nearly 22% of outstanding shares.
  • Last month, the company named the co-founder of Pale Fire Capital, Dusan Senkypl, as its Interim CEO. 
  • Price Action: GRPN shares traded higher by 2.55% at $3.82 on the last check Thursday.
Total
0
Shares
Related Posts
Read More

Analyst Ming-Chi Kuo Says “Dell’s Total Server Shipments Are Expected To Return To Significant Growth Of About 15% YOY In 2024 Thanks To Strong AI Server Demand, Well Above The Industry Average Of 3–5% YOY” – Medium

https://medium.com/@mingchikuo/dells-total-server-shipments-are-expected-to-return-to-significnat-growth-of-about-15-yoy-in-2024-d40c85c3a57f My latest supply chain check indicates that the higher-than-expected

DELL

Read More

Combangio, Inc., A Wholly Owned Subsidiary Of Kala Pharmaceuticals, Awarded $15M By California Institute For Regenerative Medicine To Support Ongoing KPI-012 Program For The Treatment Of Persistent Corneal Epithelial Defect

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today

KALA